Seagen po­si­tions Tukysa com­bo as op­tion for breast can­cer pa­tients with brain metas­tases

The com­bi­na­tion of Seagen’s Tukysa and Roche’s Kad­cy­la cut the risk of dis­ease pro­gres­sion or death by 36% in HER2-pos­i­tive breast can­cer pa­tients with brain …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER